StockDrifts LogoStockDrifts

Deep Track Capital 13F Portfolio

Portfolio Manager
Deep Track Capital LP
Performance
+25.23% (2026 Q2)
AUM (13F)
$6.87B
# of Holdings
66
Performance Rank
Allocation (Top 20)
65.43%
Latest filing
Q2 2026

Deep Track Capital LP Holdings Map

Top 50 Deep Track Capital LP Holdings

Top 10 holdings

StockCompany% Port.SharesValueActivityOwnershipAvg. CostDate
GH
GUARDANT HEALTH INC
7.5%3.39M$509.1M
+1.65%(+55.07K)
2025-Q2: 4.25M shares2025-Q3: 4.15M shares2025-Q4: 2.80M shares2026-Q1: 3.34M shares2026-Q2: 3.39M shares
$40.96(+292.23%)
2026-06-30
IMVT
IMMUNOVANT INC
5.3%9.34M$359.9M
-18.96%(-2.19M)
2025-Q2: 9.50M shares2025-Q3: 9.73M shares2025-Q4: 11.53M shares2026-Q1: 11.53M shares2026-Q2: 9.34M shares
$23.61(+77.10%)
2026-06-30
GPCR
STRUCTURE THERAPEUTICS INC
3.75%4.74M$254.4M
+10.75%(+460.22K)
2025-Q2: 5.13M shares2025-Q3: 4.22M shares2025-Q4: 4.11M shares2026-Q1: 4.28M shares2026-Q2: 4.74M shares
$33.09(+64.01%)
2026-06-30
PCVX
VAXCYTE INC
3.68%4.30M$250.0M
+0.00%(+0)
2025-Q2: 2.15M shares2025-Q3: 3.00M shares2025-Q4: 4.00M shares2026-Q1: 4.30M shares2026-Q2: 4.30M shares
$47.00(+23.57%)
2026-06-30
ALNY
ALNYLAM PHARMACEUTICALS INC
3.66%825.0K$248.3Mnew2025-Q2: 0 shares2025-Q3: 0 shares2025-Q4: 0 shares2026-Q1: 0 shares2026-Q2: 825.0K shares
$308.56(-25.90%)
2026-06-30
MANE
VERADERMICS INC
3.62%2.00M$245.9M
+300.00%(+1.50M)
2025-Q2: 0 shares2025-Q3: 0 shares2025-Q4: 0 shares2026-Q1: 500.0K shares2026-Q2: 2.00M shares
$84.71(+33.06%)
2026-06-30
TARS
TARSUS PHARMACEUTICALS INC
3.4%3.67M$230.8M
+1.85%(+66.77K)
2025-Q2: 1.75M shares2025-Q3: 3.00M shares2025-Q4: 3.00M shares2026-Q1: 3.60M shares2026-Q2: 3.67M shares
$55.60(+24.47%)
2026-06-30
NUVL
NUVALENT INC
3.24%1.78M$220.2M
+29.57%(+407.00K)
2025-Q2: 0 shares2025-Q3: 0 shares2025-Q4: 0 shares2026-Q1: 1.38M shares2026-Q2: 1.78M shares
$103.48(+19.79%)
2026-06-30
ALKS
ALKERMES PLC
3.09%4.00M$209.6M
+11.41%(+409.68K)
2025-Q2: 0 shares2025-Q3: 0 shares2025-Q4: 2.00M shares2026-Q1: 3.59M shares2026-Q2: 4.00M shares
$30.67(+59.98%)
2026-06-30
OCUL
OCULAR THERAPEUTIX INC
2.85%19.69M$193.3M
+0.00%(+0)
2025-Q2: 14.29M shares2025-Q3: 11.93M shares2025-Q4: 8.07M shares2026-Q1: 19.69M shares2026-Q2: 19.69M shares
$8.13(+23.56%)
2026-06-30

About Deep Track Capital LPโ€™s portfolio

Deep Track Capital LP reports $6.87B in US-listed equity holdings across 66 positions in its most recent 13F filing. Its largest disclosed positions are GH (7.5%), IMVT (5.3%) and GPCR (3.8%). The top 20 holdings account for 65.43% of reported assets. Its disclosed equity book has returned +111.26% on a three-year cumulative basis. Figures reflect the Q2 2026 filing.

Portfolio concentration

Portfolio concentration
GH โ€” 7.9% ($509.10M)IMVT โ€” 5.6% ($359.91M)GPCR โ€” 3.9% ($254.40M)PCVX โ€” 3.9% ($249.96M)ALNY โ€” 3.9% ($248.35M)MANE โ€” 3.8% ($245.88M)TARS โ€” 3.6% ($230.79M)NUVL โ€” 3.4% ($220.24M)ALKS โ€” 3.3% ($209.58M)OCUL โ€” 3.0% ($193.32M)Other โ€” 57.8% ($3.73B)
42%in top 10
  • GH7.9%
  • IMVT5.6%
  • GPCR3.9%
  • PCVX3.9%
  • ALNY3.9%
  • MANE3.8%
  • TARS3.6%
  • NUVL3.4%
  • ALKS3.3%
  • OCUL3.0%
  • Other57.8%

Portfolio changes

What the fund actually did

Every reported change this quarter, grouped by direction. The signal is in the rotation, not any single trade.

New buys
10
ALNYALNYLAM PHARMACEUTICALS INC3.7%
GHRSGH RESEARCH PLC1.3%
UTHRUNITED THERAPEUTICS CORP DEL1.0%
AVTXAVALO THERAPEUTICS INC1.0%
+6 opened
Added to
22
MANEVERADERMICS INC+300.0%
BMRNBIOMARIN PHARMACEUTICAL INC+187.6%
CLDXCELLDEX THERAPEUTICS INC NEW+128.9%
GMABGENMAB A/S+54.2%
+18 more
Trimmed
11
AXSMAXSOME THERAPEUTICS INC.-36.4%
IMVTIMMUNOVANT INC-19.0%
CYTKCYTOKINETICS INC-49.1%
MBXMBX BIOSCIENCES INC-37.2%
+7 more

Unlock alerts, watchlists & AI chat

Sign up free to track Deep Track Capital LP, compare funds side by side, and get alerts the moment positions change.

Source filings

Holdings on this page are parsed from Deep Track Capital LPโ€™s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 1856083). View Deep Track Capital LPโ€™s 13F filings on SEC

More 13F analyses

View all